Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Conditions
Brief summary
This study is being done to find out if patient blood samples can be used to perform individualized modeling of cancer therapy-related side effects.
Detailed description
PRIMARY OBJECTIVES: I. Generate induced pluripotent stem cells (iPSC's) from patients receiving cancer treatment. II. Differentiate patient iPSC's into cardiomyocytes and/or neurons or other cell types that may be relevant to modeling cancer therapy-related adverse effects, such as cardiotoxicity and neurotoxicity. III. Use patient specific iPSC-derived cells to: IIIa. Model cancer therapy-related toxicities; IIIb. Better understand the mechanisms of toxicities; IIIc. Determine if patient specific genetic variants are causative of toxicities; IIId. Screen novel protective therapies for cancer therapy-related toxicities. OUTLINE: This is an observational study. Patients undergo blood sample collection and have their medical records reviewed on study.
Interventions
OTHERNon-Interventional Study
Non-interventional study
Sponsors
Mayo Clinic
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Any patient \>= 18 years of age * Previously treated, planned or currently receiving any potentially toxic cancer therapy including but not limited to chemotherapy, targeted and immunotherapies
Exclusion criteria
* Inability on the part of the patient to understand the informed consent or be compliant with the protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| In vitro measurement of cellular viability in response to chemotherapy | Blood drawn at enrollment to obtain sample | Will be compared between cells derived from patients who experienced treatment-induced toxicity to cells derived from patients who received the same cancer therapy without toxicity. Statistical analyses of different endpoints will use Fisher's exact test, one-way ANOVA test followed by all-pairwise-multiple-comparison procedures, or an unpaired, two-tailed Student's t-test with significant differences defined by P \< 0.05. |
Countries
United States
Contacts
CONTACTClinical Trials Referral Office
PRINCIPAL_INVESTIGATORNadine Norton, PhD
Mayo Clinic
Outcome results
None listed